Fmr LLC Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Fmr LLC reduced its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 36.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,402 shares of the biotechnology company’s stock after selling 4,884 shares during the period. Fmr LLC’s holdings in Anavex Life Sciences were worth $48,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Anavex Life Sciences in the second quarter worth approximately $57,000. Bank of New York Mellon Corp boosted its stake in Anavex Life Sciences by 17.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock worth $1,184,000 after purchasing an additional 40,895 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Anavex Life Sciences by 15.8% during the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock worth $503,000 after buying an additional 16,293 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Anavex Life Sciences in the second quarter worth about $166,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, November 27th.

Anavex Life Sciences Trading Down 2.8 %

Shares of AVXL stock opened at $10.87 on Wednesday. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $12.48. The company’s 50-day moving average price is $7.91 and its 200-day moving average price is $6.29. The stock has a market cap of $921.73 million, a price-to-earnings ratio of -21.74 and a beta of 0.73.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, equities research analysts predict that Anavex Life Sciences Corp. will post -0.55 EPS for the current year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.